In this issue:
Familial risk of CLL
Dose escalation and resistance modulation in AML
G-CSF as supportive care after induction in AML
PML after rituximab therapy
Tipifarnib+etoposide in elderly with new AML
PET in follicular lymphoma management
Lenalidomide in mantle cell lymphoma
Bortezomib plus chemotherapy in DLBCL subtypes
Bortezomib+dexamethasone +rituximab in Waldenström macroglobulinaemia
Alcohol and malignancy risk
Please login below to download this issue (PDF)